EMA to review Hyperion's Ravicti

EMA accepted for review an MAA from Hyperion Therapeutics Inc. (NASDAQ:HPTX) for Ravicti glycerol phenylbutyrate to treat urea cycle disorders (UCDs). The pre-prodrug of phenylacetic acid is also under review in Canada. Hyperion, which markets Ravicti in the U.S. to manage chronic UCDs, has worldwide rights to the compound from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX). ...